Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D
Status:
Completed
Trial end date:
2020-12-14
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy Rifamycin SV-MMX® 600 mg
tablets for patients with diarrhoea-predominant irritable bowel syndrome when administered
two to three times daily.